Company Description
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States.
It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment.
It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions.
The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Country | United States |
Founded | 1997 |
IPO Date | Sep 21, 2004 |
Industry | Medical Instruments & Supplies |
Sector | Healthcare |
Employees | 31 |
CEO | Robert Banks |
Contact Details
Address: 380 Lackawanna Place South Orange, New Jersey 07079 United States | |
Phone | 201 343 5202 |
Website | nephros.com |
Stock Details
Ticker Symbol | NEPH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001196298 |
CUSIP Number | 640671400 |
ISIN Number | US6406714005 |
Employer ID | 13-3971809 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Robert Banks | President, Chief Executive Officer and Director |
Judy F. Krandel C.F.A. | Chief Financial Officer |
Alfred Vargas | Director of Operations |
Brianne McGuire | Director of Brand, Marketing and Business Development |
Vashone R. Thomas | Vice President of Quality, Regulatory, and Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Aug 26, 2024 | 8-K | Current Report |
Aug 8, 2024 | 10-Q | Quarterly Report |
Jun 17, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 24, 2024 | 8-K | Current Report |
May 23, 2024 | EFFECT | Notice of Effectiveness |
May 20, 2024 | UPLOAD | Filing |
May 10, 2024 | S-3 | Registration statement under Securities Act of 1933 |
May 9, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | 8-K | Current Report |
May 1, 2024 | 8-K | Current Report |